生物製剤または合成分子標的薬で治療された乾癬性関節炎患者における日和見感染: システマティックレビューとメタ解析
Front Pharmacol 2022;13:992713 doi: 10.3389/fphar.2022.992713
This is the largest meta-analysis to date, assessing the risk of OIs (Opportunistic infection) in patients with PsA. In coming to this conclusion, a systematic review and meta-analysis was undertaken to estimate the incidence of OIs following treatment with b- and tsDMARDs.
In addition, their results highlighted that bDMARDs and tsDMARDS had a low cumulative incidence of OIs in this patient group (<3% across all MOAs examined). The most common OI differed based on drug MOA. Continued evaluation of OIs is needed in post-marketing and longer-term trials to assess risk of uncommon OIs, or those with prolonged latent periods
Keywords:
